Supporting Our Colleagues: Easing the Burden of Referrals for CAR-T in Aggressive B-cell Lymphomas
October 14, 2022
Estimated Time: 1.0 hours
CME & CE Activity Release Date: October 14, 2022
CME & CE Credit Valid Through: October 29, 2023
This CE activity is intended for hematologic oncology clinicians who provide CAR-T therapy for individuals with aggressive B-cell lymphomas.
CAR T-cell therapy is a major advance in the treatment of individuals with non-Hodgkin lymphoma, especially for adult patients with relapsed or refractory large B-cell lymphoma. Several CAR-T therapies are now approved for second-line treatment, and data regarding their efficacy, safety, and real-world outcomes continue to emerge. Collaboration among hematologic oncology clinicians is needed to ensure that appropriate patients are referred for evaluation for CAR-T therapy earlier in their treatment journey, potentially offering them a better chance for lasting remission or even a cure.
During Supporting Our Colleagues: Easing the Burden of Referrals for CAR-T in Aggressive B-cell Lymphomas, expert cell therapists and a community oncologist, along with several special guests, will highlight the clinical implications of the most recent data on CAR-T therapy, explore referring clinicians’ misperceptions about access to and logistics associated with therapy, and provide practical tips to help cell therapists collaborate more effectively with referring colleagues to optimize shared care.
After completing this CE activity, the participant should be better able to:
- Assess the clinical implications of recent and emerging safety and efficacy data for CAR-T therapies
- Evaluate the implications of recent and emerging data for referring clinicians
- Respond to common questions from and misperceptions of referring clinicians
- Collaborate with the inter-professional team to facilitate logistics and access for referred patients
- Plan strategies to participate in effective shared care with referring clinicians
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, NY
Sanjay K. Juneja, MD
Hematology, Medical Oncology
Chief of Oncology Line
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Rayne H. Rouce, MD, BS
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Christopher Flowers, MD, MS
Division Head ad Interim,
Division of Cancer Medicine
Department Chair, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Crissy Kus, BSN, RN
Clinical Trial Nurse Navigator
The Leukemia & Lymphoma Society
Rye Brook, NY
This CE activity is supported through educational grants from Bristol Myers Squibb and Kite, A Gilead Company.
Educational Partner Statement
This activity is developed with our educational partner, Medical Learning Institute, Inc.
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is certified for 1.0 credit/contact hour for physicians, registered nurses, pharmacists, and physician assistants.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.